Lori A. Leslie, MD | Authors


EP. 1: Exploring CAR T-Cell Therapy in Patients with Mantle Cell Lymphoma

August 02, 2022

In an interview with Targeted OncologyTM, Leslie, assistant professor, Hackensack Meridian School of Medicine, director, Indolent Lymphoma and Chronic Lymphocytic Leukemia Research Programs, John Theurer Cancer Center, discussed the CAR T-cell product, brexucabtagene autoleucel, and its influence on both MCL and indolent lymphomas.